Related Experiment Video
Updated: Aug 6, 2026
Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Recognition and diagnosis of invasive fungal infections in neonates
Joanne L Calley1, Adilia Warris2
1Royal Aberdeen Children's Hospital, Aberdeen, UK.
Abstract:
Fungal infections largely caused by Candida species are responsible for a significant disease burden in neonates and invasive candidiasis in hospitalised neonates has high associated morbidity and mortality. Early initiation of antifungal treatment improves outcome but the recognition and diagnosis of systemic fungal infection in this population is difficult due to the non-specific clinical presentation and the high false negative rate of cultures. There is a need for a practical, sensitive and rapid diagnostic test to enhance identification and early treatment. Serum detection of (1,3)-β-d-glucan and Candida PCR are promising candidates but at present limited data exists for their use in the neonatal intensive care setting. Until such investigations are validated, early initiation of antifungal treatment on the basis of risk factor profile and clinical features remains the safest practical approach.
Insights
Diagnosing invasive fungal infections in neonates is challenging. Early antifungal treatment based on risk factors is recommended until rapid diagnostic tests are validated for neonatal intensive care units.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Mycology
Background:
- Fungal infections, primarily Candida species, cause significant disease burden in neonates.
- Invasive candidiasis in hospitalized neonates is linked to high morbidity and mortality.
- Current diagnostic methods for systemic fungal infections in neonates have limitations, including non-specific clinical presentations and high false-negative culture rates.
Purpose of the Study:
- To address the need for a practical, sensitive, and rapid diagnostic test for neonatal fungal infections.
- To evaluate the potential of serum (1,3)-β-d-glucan and Candida PCR as diagnostic tools in the neonatal intensive care setting.
Main Methods:
- Review of current diagnostic challenges for invasive fungal infections in neonates.
- Assessment of emerging diagnostic markers such as (1,3)-β-d-glucan and Candida PCR.
- Consideration of clinical risk factors and features for early treatment initiation.
Main Results:
- Limited data currently exists on the utility of (1,3)-β-d-glucan and Candida PCR in neonatal intensive care settings.
- Early diagnosis and treatment of invasive fungal infections in neonates remain difficult due to non-specific signs and unreliable cultures.
Conclusions:
- Until validated, early initiation of antifungal treatment based on risk factor profiles and clinical presentation is the most practical approach.
- Further research is needed to validate rapid diagnostic tests for invasive fungal infections in neonates.
